积极管理肥胖，降低心血管疾病风险

doi:10.12114/j.issn.1007-9572.2021.02.116

中国全科医学 ›› 2022, Vol. 25 ›› Issue (06): 643-650.DOI: 10.12114/j.issn.1007-9572.2021.02.116

所属专题：述评栏目最新文章合辑；心血管最新文章合辑；肥胖/减重最新文章合辑

• 述评 • 下一篇

积极管理肥胖，降低心血管疾病风险

郭雨阳, 曾庆春^*

510515　广东省广州市，南方医科大学南方医院心血管内科

收稿日期:2021-08-24 修回日期:2021-10-26 出版日期:2022-02-20 发布日期:2022-01-25
通讯作者: 曾庆春
基金资助:
国家自然科学基金面上项目(81770386);广东省特支计划科技创新青年拔尖人才项目(2019TQ05Y136)

Actively Managing Obesity to Reduce the Risk of Cardiovascular Disease

GUO Yuyang，ZENG Qingchun*

Department of Cardiovascular Medicine，Nanfang Hospital，Southern Medical University，Guangzhou 510515，China
*Corresponding author：ZENG Qingchun，Professor，Doctoral supervisor；E-mail：qingchunzeng@smu.edu.cn

Received:2021-08-24 Revised:2021-10-26 Published:2022-02-20 Online:2022-01-25

摘要/Abstract

摘要： 2021-04-22美国心脏协会（AHA）发布了一项关于《肥胖和心血管疾病》的声明，总结了肥胖对动脉粥样硬化性心血管疾病、心力衰竭、心源性猝死以及心房颤动诊断、临床管理以及预后的影响。本文结合我国临床的实际情况对该声明内容进行解读，以期为我国心血管内科临床实践提供参考。

关键词: 心血管疾病, 肥胖, 冠心病, 心力衰竭, 猝死, 心脏, 心房颤动

Abstract:

Obesity and Cardiovascular Disease, a statement released by the American Heart Association on April 22, 2021, gives a summary of the impact of obesity on the diagnosis, clinical management and prognosis of atherosclerotic cardiovascular disease, heart failure, sudden cardiac death and atrial fibrillation. In view of the present clinical management of cardiovascular diseases in China, this paper interprets the content of the statement in detail, aiming to provide guidance relevant to domestic cardiovascular management practices.

Key words: Cardiovascular diseases, Obesity, Coronary disease, Heart failure, Death, sudden, cardiac, Atrial fibrillation

中图分类号:

R54 R589.25

郭雨阳,曾庆春. 积极管理肥胖，降低心血管疾病风险[J]. 中国全科医学, 2022, 25(06): 643-650. DOI: 10.12114/j.issn.1007-9572.2021.02.116.

GUO Yuyang, ZENG Qingchun.

Actively Managing Obesity to Reduce the Risk of Cardiovascular Disease [J]. Chinese General Practice, 2022, 25(06): 643-650.

图/表 1

参考文献 62

[1]	POWELL-WILEY T M, POIRIER P, BURKE L E，et al. Obesity and cardiovascular disease：a scientific statement from the American heart association[J]. Circulation，2021，143(21)：e984-1010. DOI：10.1161/cir.0000000000000973.
[2]	JENSEN M D, RYAN D H, APOVIAN C M，et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society[J]. Circulation，2014，129(25 )：S102-138. DOI：10.1161/01.cir.0000437739.71477.ee.
[3]	GAO M, LV J, YU C，et al. Metabolically healthy obesity，transition to unhealthy metabolic status，and vascular disease in Chinese adults：a cohort study[J]. PLoS Med，2020，17(10)：e1003351. DOI：10.1371/journal.pmed.1003351.
[4]	AFSHIN A, FOROUZANFAR M H, REITSMA M B，et al. Health effects of overweight and obesity in 195 countries over 25 years[J]. N Engl J Med，2017，377(1)：13-27. DOI：10.1056/nejmoa1614362.
[5]	PAN X F, WANG L, PAN A. Epidemiology and determinants of obesity in China[J]. Lancet Diabetes Endocrinol，2021，9(6)：373-392. DOI：10.1016/s2213-8587(21)00045-0.
[6]	PICHÉ M E, POIRIER P, LEMIEUX I，et al. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease：an update[J]. Prog Cardiovasc Dis，2018，61(2)：103-113. DOI：10.1016/j.pcad.2018.06.004.
[7]	ASHWELL M, GIBSON S. Waist-to-height ratio as an indicator of 'early health risk’：simpler and more predictive than using a 'matrix’ based on BMI and waist circumference[J]. BMJ Open，2016，6(3)：e010159. DOI：10.1136/bmjopen-2015-010159.
[8]	SAHAKYAN K R, SOMERS V K, RODRIGUEZ-ESCUDERO J P，et al. Normal-weight central obesity：implications for total and cardiovascular mortality[J]. Ann Intern Med，2015，163(11)：827-835. DOI：10.7326/m14-2525.
[9]	COUTINHO T, GOEL K, CORRÊA DE SÁ D，et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease：role of "normal weight central obesity"[J]. J Am Coll Cardiol，2013，61(5)：553-560. DOI：10.1016/j.jacc.2012.10.035.
[10]	CAMHI S M, MUST A, GONA P N，et al. Duration and stability of metabolically healthy obesity over 30 years[J]. Int J Obes，2019，43(9)：1803-1810. DOI：10.1038/s41366-018-0197-8.
[11]	MAHABADI A A, MASSARO J M, ROSITO G A，et al. Association of pericardial fat，intrathoracic fat，and visceral abdominal fat with cardiovascular disease burden：the Framingham Heart Study[J]. Eur Heart J，2008，30(7)：850-856. DOI：10.1093/eurheartj/ehn573.
[12]	ONG K L, DING J Z, MCCLELLAND R L，et al. Relationship of pericardial fat with lipoprotein distribution：the Multi-Ethnic study of atherosclerosis[J]. Atherosclerosis，2015，241(2)：664-670. DOI：10.1016/j.atherosclerosis.2015.06.027.
[13]	GARVEY W T, MECHANICK J I, BRETT E M，et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines formedical care of patients with obesity[J]. Endocr Pract，2016，22：1-203. DOI：10.4158/EP161365.GL.
[14]	HRUSKOVA J, MAUGERI A, PODROUZKOVÁ H，et al. Association of cardiovascular health with epicardial adipose tissue and intima media thickness：the kardiovize study[J]. J Clin Med，2018，7(5)：113. DOI：10.3390/jcm7050113.
[15]	VERHEGGEN R J H M, MAESSEN M F H, GREEN D J，et al. A systematic review and meta-analysis on the effects of exercise training versus hypocaloric diet：distinct effects on body weight and visceral adipose tissue[J]. Obes Rev，2016，17(8)：664-690. DOI：10.1111/obr.12406.
[16]	FRIEDENREICH C M, NEILSON H K, O'REILLY R，et al. Effects of a high vs moderate volume of aerobic exercise on adiposity outcomes in postmenopausal women[J]. JAMA Oncol，2015，1 (6)：766. DOI：10.1001/jamaoncol.2015.2239.
[17]	RABKIN S W, CAMPBELL H. Comparison of reducing epicardial fat by exercise，diet or bariatric surgery weight loss strategies：a systematic review and meta-analysis[J]. Obes Rev，2015，16(5)：406-415. DOI：10.1111/obr.12270.
[18]	MURPHY J C, MCDANIEL J L, MORA K，et al. Preferential reductions in intermuscular and visceral adipose tissue with exercise-induced weight loss compared with calorie restriction[J]. J Appl Physiol，2012，112(1)：79-85. DOI：10.1152/japplphysiol.00355.2011.
[19]	GALLAGHER D, HESHKA S, KELLEY D E，et al. Changes in adipose tissue depots and metabolic markers following a 1-year diet and exercise intervention in overweight and obese patients with type 2 diabetes[J]. Dia Care，2014，37(12)：3325-3332. DOI：10.2337/dc14-1585.
[20]	BOGERS R P. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels：a meta-analysis of 21 cohort studies including more than 300 000 persons[J]. Arch Intern Med，2007，167(16)：1720. DOI：10.1001/archinte.167.16.1720.
[21]	SCHINDLER T H, CARDENAS J, PRIOR J O，et al. Relationship between increasing body weight，insulin resistance，inflammation，adipocytokine leptin，and coronary circulatory function[J]. J Am Coll Cardiol，2006，47(6)：1188-1195. DOI：10.1016/j.jacc.2005.10.062.
[22]	QUERCIOLI A, MONTECUCCO F, PATAKY Z，et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric by pass-induced weight loss：relation to alterations in endocannabinoids and adipocytokines[J]. Eur Heart J，2013，34(27)：2063-2073. DOI：10.1093/eurheartj/eht085.
[23]	The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Metabolic mediators of the effects of body-mass index，overweight，and obesity on coronary heart disease and stroke：a pooled analysis of 97 prospective cohorts with 1.8 million participants[J]. Lancet，2014，383(9921)：970-983. DOI：10.1016/S0140-6736(13)61836-X.
[24]	HIBBERT B, SIMARD T, WILSON K R，et al. Transradial versus transfemoral artery approach for coronary angiography and percutaneous coronary intervention in the extremely obese[J]. JACC：Cardiovasc Interv，2012，5(8)：819-826. DOI：10.1016/j.jcin.2012.04.009.
[25]	ELAGIZI A, KACHUR S, LAVIE C J，et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases[J]. Prog Cardiovasc Dis，2018，61(2)：142-150. DOI：10.1016/j.pcad.2018.07.003.
[26]	CARBONE S, CANADA J M, BILLINGSLEY H E，et al. Obesity paradox in cardiovascular disease：where do we stand?[J]. Vasc Health Risk Manag，2019，15：89-100. DOI：10.2147/VHRM.S168946.
[27]	LAVIE C J, DE SCHUTTER A, PATEL D A，et al. Body composition and survival in stable coronary heart disease：impact of lean mass index and body fat in the "obesity paradox" [J]. J Am Coll Cardiol，2012，60(15)：1374-1380. DOI：10.1016/j.jacc.2012.05.037.
[28]	SJÖSTRÖM L, PELTONEN M, JACOBSON P，et al. Bariatric surgery and long-term cardiovascular events[J]. JAMA，2012，307(1)：56-65. DOI：10.1001/jama.2011.1914.
[29]	The Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes：a post-hoc analysis of the Look AHEAD randomised clinical trial[J]. Lancet Diabetes Endocrinol，2016，4(11)：913-921. DOI：10.1016/S2213-8587(16)30162-0.
[30]	FISHER D P, JOHNSON E, HANEUSE S，et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity[J]. JAMA，2018，320(15)：1570. DOI：10.1001/jama.2018.14619.
[31]	PAYVAR S, KIM S, RAO S V，et al. In-hospital outcomes of percutaneous coronary interventions in extremely obese and normal-weight patients：findings from the NCDR （National Cardiovascular Data Registry）[J]. J Am Coll Cardiol，2013，62(8)：692-696. DOI：10.1016/j.jacc.2013.05.058.
[32]	BUSCHUR M, SMITH D, MOSCUCCI M，et al. The burgeoning epidemic of obesity in patients undergoing percutaneous coronary intervention （PCI）：insight from the blue cross blue shield of Michigan cardiovascular consortium （bmc2）[J]. J Am Coll Cardiol，2012，59(13)：E54. DOI：10.1016/S0735-1097(12)60055-2.
[33]	HOLROYD E W, SIRKER A, KWOK C S，et al. The relationship of body mass index to percutaneous coronary intervention outcomes：does the obesity paradox exist in contemporary percutaneous coronary intervention cohorts? Insights from the British cardiovascular intervention society registry[J]. JACC：Cardiovasc Interv，2017，10(13)：1283-1292. DOI：10.1016/j.jcin.2017.03.013.
[34]	TERADA T, FORHAN M, NORRIS C M，et al. Differences in short- and long-term mortality associated with BMI following coronary revascularization[J]. J Am Heart Assoc，2017，6(4)：e005335. DOI：10.1161/jaha.116.005335.
[35]	PARK D W, KIM Y H, YUN S C，et al. Association of body mass index with major cardiovascular events and with mortality after percutaneous coronary intervention[J]. Circ Cardiovasc Interv，2013，6(2)：146-153. DOI：10.1161/CIRCINTERVENTIONS.112.000062.
[36]	MA W Q, SUN X J, WANG Y，et al. Does body mass index truly affect mortality and cardiovascular outcomes in patients after coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft? A systematic review and network meta-analysis[J]. Obes Rev，2018，19(9)：1236-1247. DOI：10.1111/obr.12713.
[37]	BHATT D L, GROSSER T, DONG J F，et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus[J]. J Am Coll Cardiol，2017，69(6)：603-612. DOI：10.1016/j.jacc.2016.11.050.
[38]	BORDEAUX B C, QAYYUM R, YANEK L R，et al. Effect of obesity on platelet reactivity and response to low-dose aspirin[J]. Prev Cardiol，2010，13(2)：56-62. DOI：10.1111/j.1751-7141.2009.00058.x.
[39]	TERADA T, JOHNSON J A, NORRIS C，et al. Severe obesity is associated with increased risk of early complications and extended length of stay following coronary artery bypass grafting surgery[J]. J Am Heart Assoc，2016，5(6)：e003282. DOI：10.1161/jaha.116.003282.
[40]	WAGNER B D, GRUNWALD G K, RUMSFELD J S，et al. Relationship of body mass index with outcomes after coronary artery bypass graft surgery[J]. Ann Thorac Surg，2007，84(1)：10-16. DOI：10.1016/j.athoracsur.2007.03.017.
[41]	CHASSÉ M, MATHIEU P, VOISINE P，et al. The underestimated belly factor：waist circumference is linked to significant morbidity following isolated coronary artery bypass grafting[J]. Can J Cardiol，2016，32(3)：327-335. DOI：10.1016/j.cjca.2015.06.031.
[42]	CHIEN S C, CHANDRAMOULI C, LO C I，et al. Associations of obesity and malnutrition with cardiac remodeling and cardiovascular outcomes in Asian adults：a cohort study[J]. PLoS Med，2021，18(6)：e1003661. DOI：10.1371/journal.pmed.1003661.
[43]	HORWICH T B, FONAROW G C, CLARK A L. Obesity and the obesity paradox in heart failure[J]. Prog Cardiovasc Dis，2018，61(2)：151-156. DOI：10.1016/j.pcad.2018.05.005.
[44]	PANDEY A, PATEL K V, VADUGANATHAN M，et al. Physical activity，fitness，and obesity in heart failure with preserved ejection fraction[J]. JACC Heart Fail，2018，6(12)：975-982. DOI：10.1016/j.jchf.2018.09.006.
[45]	PANDEY A, LAMONTE M, KLEIN L，et al. Relationship between physical activity，body mass index，and risk of heart failure[J]. J Am Coll Cardiol，2017，69(9)：1129-1142. DOI：10.1016/j.jacc.2016.11.081.
[46]	BOZKURT B, AGUILAR D, DESWAL A，et al. Contributory risk and management of comorbidities of hypertension，obesity，diabetes mellitus，hyperlipidemia，and metabolic syndrome in chronic heart failure：a scientific statement from the American heart association[J]. Circulation，2016，134(23). DOI：10.1161/cir.0000000000000450.
[47]	LAVIE C J, LADDU D, ARENA R，et al. Reprint of：healthy weight and obesity prevention：JACC health promotion series[J]. J Am Coll Cardiol，2018，72(23 Pt B)：3027-3052. DOI：10.1016/j.jacc.2018.10.024.
[48]	EMAMI A, SAITOH M, VALENTOVA M，et al. Comparison of sarcopenia and cachexia in men with chronic heart failure：results from the Studies Investigating Co-morbidities Aggravating Heart Failure （SICA-HF）[J]. Eur J Heart Fail，2018，20(11)：1580-1587. DOI：10.1002/ejhf.1304.
[49]	GHOSH R K, GHOSH G C, GUPTA M，et al. Sodium glucose Co-transporter 2 inhibitors and heart failure[J]. Am J Cardiol，2019，124(11)：1790-1796. DOI：10.1016/j.amjcard.2019.08.038.
[50]	JORSAL A, KISTORP C, HOLMAGER P，et al. Effect of liraglutide，a glucagon-like peptide-1 analogue，on left ventricular function in stable chronic heart failure patients with and without diabetes （LIVE）—a multicentre，double-blind，randomised，placebo-controlled trial[J]. Eur J Heart Fail，2017，19(1)：69-77. DOI：10.1002/ejhf.657.
[51]	VIEIRA J L, MEHRA M R. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med，2020，382(10)：972-973. DOI：10.1056/NEJMc1917241.
[52]	RODRIGUEZ FLORES M, AGUILAR SALINAS C, PICHÉ M E，et al. Effect of bariatric surgery on heart failure[J]. Expert Rev Cardiovasc Ther，2017，15(8)：567-579. DOI：10.1080/14779072.2017.1352471.
[53]	KOSHINO Y, VILLARRAGA H R, SOMERS V K，et al. Changes in myocardial mechanics in patients with obesity following major weight loss after bariatric surgery[J]. Obesity，2013，21(6)：1111-1118. DOI：10.1002/oby.20168.
[54]	SHIMADA Y J, TSUGAWA Y, BROWN D F M，et al. Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation：population-based，self-controlled series[J]. J Am Coll Cardiol，2016，67(8)：895-903. DOI：10.1016/j.jacc.2015.12.016.
[55]	LAVIE C J, MEHRA M R, VENTURA H O. Body composition and advanced heart failure therapy：weighing the options and outcomes[J]. JACC：Heart Fail，2016，4(10)：769-771. DOI：10.1016/j.jchf.2016.07.007.
[56]	AUNE D, SCHLESINGER S, NORAT T，et al. Body mass index，abdominal fatness，and the risk of sudden cardiac death：a systematic review and dose-response meta-analysis of prospective studies[J]. Eur J Epidemiol，2018，33(8)：711-722. DOI：10.1007/s10654-017-0353-9.
[57]	SHAHREYAR M, DANG G, WAQAS BASHIR M，et al. Outcomes of in-hospital cardiopulmonary resuscitation in morbidly obese patients[J]. JACC：Clin Electrophysiol，2017，3(2)：174-183. DOI：10.1016/j.jacep.2016.08.011.
[58]	WONG C X, SULLIVAN T, SUN M T，et al. Obesity and the risk of incident，post-operative，and post-ablation atrial fibrillation：a meta-analysis of 626，603 individuals in 51 studies[J]. JACC Clin Electrophysiol，2015，1(3)：139-152. DOI：10.1016/j.jacep.2015.04.004.
[59]	TSANG T S M, BARNES M E, MIYASAKA Y，et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation：a longitudinal cohort study of 21 years[J]. Eur Heart J，2008，29(18)：2227-2233. DOI：10.1093/eurheartj/ehn324.
[60]	WONG C X, SUN M T, ODUTAYO A，et al. Associations of epicardial，abdominal，and overall adiposity with atrial fibrillation[J]. Circ：Arrhythmia Electrophysiol，2016，9(12). DOI：10.1161/circep.116.004378.
[61]	ABED H S, WITTERT G A, LEONG D P，et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation[J]. JAMA，2013，310(19)：2050. DOI：10.1001/jama.2013.280521.
[62]	PATHAK R K, MIDDELDORP M E, MEREDITH M，et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort：a long-term follow-up study （LEGACY）[J]. J Am Coll Cardiol，2015，65(20)：2159-2169. DOI：10.1016/j.jacc.2015.03.002.

诊断方式		优点	缺点	注意事项
非侵入性检查
	心电图	便捷，便宜	灵敏度、特异度低，受肥胖影响	肥胖可导致心率增快、QRS间期延长、QT间期延长、假阳性的下壁心肌梗死等心电图改变
	平板运动试验	便捷	患者可能会因为与心血管疾病无关的症状而停止	肥胖患者的峰值心率、心率恢复和变时指数均较低
	SPECT	精度高	有辐射，技术上对体型有限制，肥胖患者常见乳房和膈肌的衰减伪影，相对灌注显像对三支病变或左主干病变的检测能力降低	对于体质量较大的患者〔250~350磅（113~160 kg）〕，建议采用为期2 d、剂量较大的示踪剂方案，体质量上限约为350磅（160 kg）
	PET（铷）	较SPECT成像效果更好，辐射更小，伪影和衰减少；可绝对定量冠状动脉血流，适用于三支病变及左主干病变	对体型有限制	-
	负荷超声心动图	便捷，适用于肥胖患者，无辐射，无体质量/体型限制，功能性测试	对操作者要求高，受肺部疾病、乳房大小、肥胖、呼吸运动影响	-
	负荷心脏MRI	可准确评估慢性压力负荷和心排血量高的复杂心脏效应，肥胖对此项检查影响小	对体质量、体型等有限制，幽闭恐怖症患者不适用	MRI台的重量限制为335磅（152 kg）
	心脏CT钙扫描	经济、重复性好，可测定冠状动脉疾病程度	肥胖可能限制心脏CT钙扫描的诊断准确性和价值，仪器内径对体型有限制	CT设备的台面重量限制为350~450磅（160~204 kg）
	冠状动脉CT增强扫描	检测肥胖患者的灵敏度和阴性预测值较高	图像质量、信噪比随BMI的增加而下降，肥胖患者血管不可评估段的比例更高	-
侵入性检查
	冠状动脉造影	冠状动脉疾病诊断的金标准	肥胖患者血管通路不畅，并发症更多，为达到足够的透视度，肥胖患者和术者需要接受更高的辐射	肥胖患者首选桡动脉通路，桡动脉入路的并发症发生率比股动脉入路低3倍^[24]；如采用股动脉入路，应使用血管闭合装置缩短肥胖患者检查至下床活动时间
	血管内超声	可对斑块负荷、斑块形态（即斑块发展阶段、高风险斑块特征）进行体内评估	侵入性操作	-

诊断方式		优点	缺点	注意事项
非侵入性检查
	心电图	便捷，便宜	灵敏度、特异度低，受肥胖影响	肥胖可导致心率增快、QRS间期延长、QT间期延长、假阳性的下壁心肌梗死等心电图改变
	平板运动试验	便捷	患者可能会因为与心血管疾病无关的症状而停止	肥胖患者的峰值心率、心率恢复和变时指数均较低
	SPECT	精度高	有辐射，技术上对体型有限制，肥胖患者常见乳房和膈肌的衰减伪影，相对灌注显像对三支病变或左主干病变的检测能力降低	对于体质量较大的患者〔250~350磅（113~160 kg）〕，建议采用为期2 d、剂量较大的示踪剂方案，体质量上限约为350磅（160 kg）
	PET（铷）	较SPECT成像效果更好，辐射更小，伪影和衰减少；可绝对定量冠状动脉血流，适用于三支病变及左主干病变	对体型有限制	-
	负荷超声心动图	便捷，适用于肥胖患者，无辐射，无体质量/体型限制，功能性测试	对操作者要求高，受肺部疾病、乳房大小、肥胖、呼吸运动影响	-
	负荷心脏MRI	可准确评估慢性压力负荷和心排血量高的复杂心脏效应，肥胖对此项检查影响小	对体质量、体型等有限制，幽闭恐怖症患者不适用	MRI台的重量限制为335磅（152 kg）
	心脏CT钙扫描	经济、重复性好，可测定冠状动脉疾病程度	肥胖可能限制心脏CT钙扫描的诊断准确性和价值，仪器内径对体型有限制	CT设备的台面重量限制为350~450磅（160~204 kg）
	冠状动脉CT增强扫描	检测肥胖患者的灵敏度和阴性预测值较高	图像质量、信噪比随BMI的增加而下降，肥胖患者血管不可评估段的比例更高	-
侵入性检查
	冠状动脉造影	冠状动脉疾病诊断的金标准	肥胖患者血管通路不畅，并发症更多，为达到足够的透视度，肥胖患者和术者需要接受更高的辐射	肥胖患者首选桡动脉通路，桡动脉入路的并发症发生率比股动脉入路低3倍^[24]；如采用股动脉入路，应使用血管闭合装置缩短肥胖患者检查至下床活动时间
	血管内超声	可对斑块负荷、斑块形态（即斑块发展阶段、高风险斑块特征）进行体内评估	侵入性操作	-

积极管理肥胖，降低心血管疾病风险

Actively Managing Obesity to Reduce the Risk of Cardiovascular Disease

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 62

相关文章 15

编辑推荐

Metrics

留言

[1]	易珊烨, 杨荣, 廖晓阳, 周伊恒, 刘力滴, 杨梓钰, 白佳欣, 贾禹, 张欣. 2024年《动脉压力、结构及功能评估》专家共识解读[J]. 中国全科医学, 2026, 29(32): 4690-4694.
[2]	杨宇青, 李文哲, 朱利杰, 杨廷杰, 郭一鸣, 陈璐琳, 曹煜栋, 袁江淑, 杨宏辉. 冠心病患者中性粒细胞百分比与白蛋白比值与冠状动脉钙化的相关性研究[J]. 中国全科医学, 2026, 29(30): 4390-4396.
[3]	李兰, 刘力滴, 张鹏, 李东泽, 杨梓钰, 程永浪, 廖晓阳, 万智. 基于生活方式干预措施的体重管理：2025版NICE《超重和肥胖的管理（NG246）》指南部分更新亮点解读[J]. 中国全科医学, 2026, 29(30): 4353-4359.
[4]	付晓雅, 杨菲, 顾可羿, 顾瀚东, 王为强. 心血管代谢共病患者相对脂肪质量指数与估算肾小球滤过率下降的相关性探究[J]. 中国全科医学, 2026, 29(28): 4187-4192.
[5]	张涵, 蔡根深, 冯郑文, 张恺悦, 廉东波, 张华, 张晶. 分级诊疗背景下北京市肥胖症共病相关卫生服务可得性评估：基于医疗机构的调查研究[J]. 中国全科医学, 2026, 29(28): 4117-4124.
[6]	蒋晨, 安妮, 徐运璟, 牛少娜, 李凤鸣, 姜良美. 心血管-肾脏-代谢综合征患者住院特征及医疗资源消耗的横断面研究[J]. 中国全科医学, 2026, 29(28): 4172-4178.
[7]	卢鸿润, 张睿, 赵钰, 李佳禛, 王为强. 心血管代谢性共病与估算肾小球滤过率的关联性研究[J]. 中国全科医学, 2026, 29(28): 4179-4186.
[8]	张颖, 唐以俊, 刘力滴, 蒋莉华, 贾禹, 杨荣, 杨梓钰, 廖晓阳. 中国肥胖儿童青少年心血管代谢风险管理：基于2024年意大利儿科内分泌学和糖尿病学会《肥胖儿童和青少年的心血管代谢风险》立场文件[J]. 中国全科医学, 2026, 29(27): 3879-3887.
[9]	付梦茹, 薛梅启旸, 蒋雨桐, 陈鸣声, 钱东福, 李忠. 农村心房颤动患者自我管理能力影响因素研究[J]. 中国全科医学, 2026, 29(27): 3947-3955.
[10]	郭俊池, 张明妍, 秦广宁, 徐强, 路美娟. 新型指标TANS01在痰湿体质人群心血管风险评估中的初步应用研究[J]. 中国全科医学, 2026, 29(27): 3924-3930.
[11]	张涵予, 陈晓南, 黄延焱. 澳大利亚全科医生学会《全科医学的预防活动指南》解读与讨论：心房颤动的筛查与发现在全科医学中的意义[J]. 中国全科医学, 2026, 29(27): 3888-3890.
[12]	王伟, 于飞, 闫晓红. 钠-葡萄糖协同转运蛋白2抑制剂在不同病因心力衰竭中的应用与机制：来自缺血性与非缺血性心力衰竭的证据[J]. 中国全科医学, 2026, 29(27): 3976-3984.
[13]	杨芮, 廖晓阳, 黄传应, 杨梓钰, 沈灿, 贾禹, 刘力滴, 杨荣. 2024英国和爱尔兰高血压协会立场声明：青年高血压的调查与管理解读[J]. 中国全科医学, 2026, 29(26): 3726-3732.
[14]	赵原原, 刘普林, 代娟, 张刚, 张微, 张晓霞, 邓青, 严亚琼. 中国内脏脂肪指数与老年人全因死亡及死因别死亡风险的关联研究[J]. 中国全科医学, 2026, 29(26): 3781-3787.
[15]	董澳, 赵乃慧, 欧文丽, 陈朔华, 汪国栋, 戴璐尧, 刘灿章, 吴寿岭, 杨秀红. 心脏代谢指数与慢性肾脏病发病风险的关联：一项前瞻性队列研究[J]. 中国全科医学, 2026, 29(25): 3614-3623.